PART I Item 1. Bu siness. Overview We are a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, repla...
expected 2026-11-05
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001193125-26-071593 | EDGAR | 87K words |
| 2025-02-26 | 2024-12-31 | 0000950170-25-027758 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021183 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005111 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0000950170-22-001979 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008860 | EDGAR | — |
| 2020-03-24 | 2019-12-31 | 0001564590-20-012520 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001564590-19-009358 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-338052 | EDGAR | — |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269592 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105050 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066987 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122328 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092814 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055682 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060270 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-038023 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017874 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023249 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014810 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-338008 | EDGAR | — |
| 2026-02-25 | 0001193125-26-071557 | EDGAR | 2K words |
| 2025-12-12 | 0001193125-25-317554 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269537 | EDGAR | — |
| 2025-10-21 | 0001193125-25-245102 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105023 | EDGAR | — |
| 2025-06-13 | 0001193125-25-140731 | EDGAR | — |
| 2025-05-08 | 0000950170-25-066945 | EDGAR | — |
| 2025-03-28 | 0000950170-25-046756 | EDGAR | — |
| 2025-03-10 | 0001193125-25-050448 | EDGAR | — |
125 total filings indexed. 95 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001653087 |
| Ticker | ALEC |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.alector.com |
| Listed | 2019-02-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ALEC (~200 tokens, structured JSON with cryptographic provenance)